Progyny, Inc. Research and Development Expense
Progyny, Inc. (PGNY) reported Research and Development Expense of $3.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-07
- Progyny, Inc. research and development expense for the quarter ending 2026-06-30 was $3.30M, a 43.48% increase year-over-year.
- Progyny, Inc. research and development expense for the quarter ending 2026-03-31 was $2.80M, a 86.67% increase year-over-year.
- Progyny, Inc. research and development expense for the quarter ending 2025-12-31 was $3.10M.
- Progyny, Inc. research and development expense for the quarter ending 2025-09-30 was $2.60M.
- Progyny, Inc. research and development expense for fiscal 2025 was $9.50M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.30M 10-Q · filed 2026-08-07 | $6.10M 10-Q · filed 2026-08-07 | $9.20M derived: sum of 3 quarters · filed 2026-08-07 | $11.80M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $2.80M 10-Q · filed 2026-05-08 | $5.90M derived: sum of 2 quarters · filed 2026-05-08 | $8.50M derived: sum of 3 quarters · filed 2026-05-08 | $10.80M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $5.70M derived: sum of 2 quarters · filed 2026-02-27 | $8.00M derived: sum of 3 quarters · filed 2026-08-07 | $9.50M 10-K · filed 2026-02-27 |
| 2025-09-30 | $2.60M 10-Q · filed 2025-11-07 | $4.90M derived: sum of 2 quarters · filed 2026-08-07 | $6.40M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $2.30M 10-Q · filed 2026-08-07 | $3.80M 10-Q · filed 2026-08-07 | ||
| 2025-03-31 | $1.50M 10-Q · filed 2026-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |